BioBull

BioBull long only

[PDUFA Pulse @PDUFA_Pulse]

Two FDA clocks are live this morning, but for different reasons:

$REPL — Aug. 2 goal passed; no public outcome
$MRNA — Aug. 5 goal date is today

One is a disclosure-status problem. One is a label/pathway decision.

“Pending” is the same word—not the same setup.

[Joe @Gantosj]

Totally agree, $LIB.v $VLTLF is on a trajectory that could realistically land it on the Nasdaq.
And a year from now, the valuation being 10× higher isn’t a stretch in my opinion.
This isn’t just "scaling up" ... It's about multiplying units across the entire Permian Basin 🚀

[BioBull @BioBull4]

Do you remember when you joined X? I do! #MyXAnniversary

[BioBull @BioBull4]

Insider trading by congress members should be illegal, the same as any other US citizen that can't use insider info to make millions of dollars gain. $SPY $QQQ

[Mr. Star Spangled MAGA @4thOfJuly365]

Excellent question 🤔

[zohm @zohmbastic]

$NKTR
H.C. Wainwright raised the firm's price target on Nektar to $185 from $165 and keeps a Buy rating on the shares after the company reported "strong" 16-week treatment extension data from the ongoing Phase 2b REZOLVE-AA study. These "compelling results" could help significantly overcome investors' skepticism and further solidify rezpeg's potential in alopecia areata, the analyst contends.

[Ripster @ripster47]

🚨Rare Earth back on rotation watch as both $MP & $USAR have news this morning
$USAR $MP solid longs
@tenet_research

[BiotechTV @BiotechTV]

𝐁𝐫𝐢𝐠𝐡𝐭 𝐌𝐢𝐧𝐝𝐬: Physican and Biotech Investor @A_May_MD reacts to this morning's 52 week Rezpeg data in alopecia from Nektar. $NKTR

Full video: https://t.co/PtFCDd94ib

[ChimeraResearchGroup @ChimeraResearch]

$MDNAF $MDNA.to just rolled out a fresh, sleek& highly professional new website
A well‑timed upgrade ahead of MDNA113 data release at #AACR26 & @BloomBurton conference-Toronto

Smart move, presentation matters, especially going into a catalyst-heavy period
https://t.co/Y1wvMHRFgJ

[ChimeraResearchGroup @ChimeraResearch]

All followers of Joe @Gantosj should follow @ChimeraResearch to get updates from the #Biotech BloomBurton conference in Toronto on Tue &Wed

Until Joe regains access to his hacked X account. Presenting companies including $ZYME $EPRX $MDNAF $CNVI.v $MSLE $PYNKF $NGEN $XENE &more

[Bio Stocks™ @BioStocks]

$NKTR
SALT ≤20: 25.8% (low-dose, up from 14.8% at week 36) and 27.6% (high-dose, up from 15.6%) versus 6.7% placebo (p=0.049).

SALT ≤30 (≥70% scalp hair): 30.2% (low-dose, up from 21.9%) and 35.0% (high-dose, up from 29.0%) versus 8.4% placebo (p=0.023).

[dough @semodough]

$NKTR JEFF believe there will be a market and great need for Rezpeg in the AA space, given the dearth of
biologics available to pts, esp for those who are unable or unwilling to use a JAKi due to comorbidities
and/ or safety concerns. We esp see Rezpeg's novel MOA and clean safety profile as stand-out features
and continue to see a strong commercial oppt'y for Rezpeg as the potentially first biologic in AA w/ an
efficacy that is at the low end of JAKi's (validated by market research).

[Bio Stocks™ @BioStocks]

$NKTR trading resumes

[ChimeraResearchGroup @ChimeraResearch]

Curious to see how high $CNVI.v can run after FDA clearance

I’ll be watching for a breakout above C$0.83 resistance & opens the door upside toward C$1.00

For the US $CNVIF that lines up with ~ US$0.73

Let’s hope broader market conditions don’t interfere with the momentum.

[ChimeraResearchGroup @ChimeraResearch]

Exactly $CNVI.v $CNVIF is a prime buy-out target!
The ONLY co-aligned IVUS-OCT Platform in the market

With a growing #Intravascular Imaging market over $1 Billion, the large #MedTech companies will get alerted & try to get M&A sooner than later!

[Joe @Gantosj]

A surprising & frankly greedy move by @X @elonmusk

Millions of users were told to pay for X Premium to keep using TweetDeck.
Now X has pushed TweetDeck into Premium+, raising the cost >5× from $102 to $560

No doubt @X is going to face a lot of backlash for this decision.🤮🤮

[BioBull @BioBull4]

@Gantosj Thanks Joe, really appreciate your hard work & sharing your ideas with us, for me $VLTLF was great pick and kept adding at every dip to ends up with an extra large position (for my size LOL)

[BioBull @BioBull4]

I 100% agree with Joel, @joinyellowbrick is missing the person who first brought the $VLTLF $LIB.v idea back in June 2024, when Volt #Lithium was only a C$58M market cap, now C$267M

Huge thanks to Joe @Gantosj & $ChimeraResearch for the incredible find
https://t.co/xtqPo1tW1C

[Joel @StunningFeline]

@joinyellowbrick @NestBetter @AlmostMongolian Should tag @ChimeraResearch and @Gantosj who pitched it way before November :)

[Joe @Gantosj]

With cash in the bank, $CNVIF $CNVI.V is gearing up to launch ahead of the anticipated FDA clearance for their next-gen system!

$CNVI.V groundbreaking hybrid IVUS-OCT #intravascular imaging gives surgeons the best of both worlds, high-resolution detail from OCT + deeper anatomical views from IVUS ....all in one catheter! #intravascularimaging #MedTech"

[BioBull @BioBull4]

@Sahsanjay5 @Gantosj It's mostly trading with large volume in Canada $CRI.v and very light in the US $CRICF hard to get large order filled.